Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 19Unknown 13Terminated 10Recruiting 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 36INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Non-squamous Non-small Cell Lung Cancer 1Carcinoma, Hepatocellular 1

Interventions

Injections 41Carboplatin 34Cisplatin 24Capecitabine 24Paclitaxel 23Docetaxel 23pembrolizumab 21Oxaliplatin 21Gemcitabine 20Pemetrexed 19Bevacizumab 18Fluorouracil 13Irinotecan 12Cyclophosphamide 12osimertinib 9Nivolumab 8Dexamethasone 8tislelizumab 7Topotecan 7Leucovorin 7Doxorubicin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6regorafenib 6lenvatinib 6fludarabine 6Rituximab 6Cetuximab 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × camrelizumab × Clear all
NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Shanghai Shengdi Pharmaceutical Co., Ltd

Phase 2/3 Not yet recruiting
401 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

CNBG-Virogin Biotech (Shanghai) Ltd.

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡